Phase 1 Study to Evaluate How Oral Emraclidine Is Processed and Its Safety in Healthy Adults Aged 65 to 85

What this Trial Is About

Researchers are evaluating how the drug emraclidine, taken orally, moves through the bodies of healthy elderly adults aged 65 to 85. This Phase 1 study aims to assess the safety, tolerability, and any adverse events related to emraclidine. Participants are healthy volunteers without significant medical conditions, providing important information about how the drug behaves in older adults. Participants will receive oral doses of either emraclidine or a placebo for periods of 10 or 17 days. The study uses a randomized, placebo-controlled design with multiple ascending oral doses to compare how the drug and placebo affect the body. The treatment groups receive the study medication or placebo under close monitoring during these dosing periods. During the study, participants will undergo various assessments including medical history reviews, physical exams, vital signs, electrocardiograms ECGs, and lab tests. Researchers will track adverse events and changes in clinical measures such as movement scales and suicide risk rating scales up to approximately 20 to 50 days. Blood samples will be collected to measure drug levels and how the body processes emraclidine. Overall participation involves careful safety monitoring and evaluation of how the drug is tolerated in healthy elderly adults.

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants